Back

Predicting individual blood pressure response to additional antihypertensive treatment: a prototype decision support tool for healthcare professionals in the community

30 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Ajay Gupta

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Baseline characteristics and antihypertensive patterns in Finnish patients with hypertension and kidney disease
Professor T. Niiranen (Turku, FI)
Abstract Slides
Presentation thumbnail
Artificial intelligence-assisted personalised dose titration for hypertension: safety and feasibility results of the CURATE.AI pilot randomised controlled trial
Doctor X. Tadeo (Singapore, SG)
Abstract Slides
Presentation thumbnail
Renal function and hyperkalemia with first-line eplerenone in obese patients with hypertension: randomized safety data from the HEBRO trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Digital AI lifestyle support improves blood pressure control on top of standard dual antihypertensive therapy
Mr B. Rozibaev (Tashkent, UZ)
Abstract Slides
Presentation thumbnail
Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care
Doctor J. Wang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy in hypertension

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Tailored interventions to improve adherence to antihypertensive treatment and reduce blood pressure: findings from a systematic review and meta-analysis
5 April 2025
thumbnail
Congress Presentation
Identification of predictors of response to initial oral combination therapy in WHO-functional class II or III PAH patients: A post-hoc analysis of the AMBITION study
28 August 2020
thumbnail
Congress Presentation
Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial
30 June 2021
thumbnail
Congress Presentation
Successful perindopril/amlodipine+indapamide treatment as second line in uncontrolled hypertensive patients in line with european guidelines
7 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources